patient enrolment begins april 2010, page-6

There is an interesting Australian trifecta of biotechnology stocks based upon common directors/unique technologies/small market caps and tremendous potential for growth.

Dr Douglas Wilson, Director and Chief Medical Officer for NEU is also the Executive Chairman of Phylogica PYC. Dr Paul Watt, CEO of PYC is also a Director of Avita Medical AVH. I can recommend a recent post which I submitted on Phylogica for some background. The management calibre and technology and business platforms of all three companies are world class.

I was looking back at some of the big volume movements in NEU during the past 12 months. There were significant volumes in April 09 but nothing compared to July 1 when 231m shares passed hands - day traders frenzy. It does also suggest the reasons for volume selling at 3-4c despite the commencement of Neuren's Phase II trial which could transfrom the company into a major biotechnology player. Stale longs.

We probably have all being stale longs at one time or another. Stale longs just want the pain to end no matter what the future potential - good news simply provides the depth to sell into and exit stage left.